What are the best treatments for IgA nephropathy?

TL;DR: Treatment for IgA nephropathy focuses on slowing kidney damage through blood pressure management, protein-lowering medications, and targeted immunosuppression. The most effective approach is highly personalized, requiring a multidisciplinary team to balance disease progression risk against the potential side effects of therapy.

What are the first-line treatments for IgA nephropathy?

The primary goal in managing IgA nephropathy is to reduce proteinuria (protein in the urine) and maintain stable blood pressure, as these factors are the strongest predictors of long-term kidney function. According to the Kidney Disease: Improving Global Outcomes (KDIGO) guidelines, the initial treatment for IgA nephropathy almost always includes supportive care. This involves the use of renin-angiotensin-aldosterone system (RAAS) inhibitors, specifically ACE inhibitors or ARBs, which help protect the kidneys by reducing pressure within the glomerular filtration units.

Which medications are commonly prescribed for IgA nephropathy?

For patients with persistent proteinuria despite optimal supportive care, physicians may introduce additional therapies. Medications commonly prescribed for IgA nephropathy include:

• RAAS Inhibitors: Lisinopril, ramipril, losartan, or valsartan (e.g., Diovan).


• SGLT2 Inhibitors: Drugs like dapagliflozin (Farxiga) have recently become a cornerstone of treatment to slow the decline of kidney function.


• Immunosuppressants: Corticosteroids (e.g., prednisone) may be used for high-risk patients, though they carry significant side-effect profiles.


• Targeted Therapies: Targeted-release budesonide (Tarpeyo) is an FDA-approved option specifically designed to target the gut-associated lymphoid tissue, which is believed to be the source of the pathogenic IgA antibodies in IgA nephropathy.

What non-pharmacological approaches are recommended?

While there is no surgical cure for IgA nephropathy, lifestyle modifications are essential to preserve kidney health. A low-sodium diet is frequently recommended to assist in blood pressure control, and smoking cessation is critical, as smoking accelerates renal decline. Patients should work with a renal dietitian to manage protein and potassium intake based on their current stage of kidney function.

Are there emerging treatments or clinical trials?

The landscape for IgA nephropathy research is evolving rapidly. Current clinical trials are investigating B-cell depleting therapies, complement inhibitors, and endothelin receptor antagonists. Because IgA nephropathy is a complex autoimmune condition, researchers are focused on identifying biomarkers that can predict which patients will progress to end-stage renal disease, allowing for more precise, early intervention.

How does the care team support patients?

Managing IgA nephropathy requires a multidisciplinary approach to address both the physical and emotional burdens of the disease. Your care team should ideally include:

• Nephrologist: The lead specialist managing kidney function and medication titration.


• Renal Dietitian: To provide tailored nutritional guidance.


• Clinical Psychologist: To support patients navigating the anxiety of a chronic, unpredictable condition.


• Genetic Counselor: To discuss familial risks, as IgA nephropathy can have a hereditary component in some families.

Within our DiseaseMaps community, 347 people with IgA nephropathy have shared their experiences, highlighting the importance of peer support in managing the daily realities of this diagnosis.

Next steps

• Consult your nephrologist to discuss whether your current proteinuria levels warrant a change in therapy.


• Request a referral to a renal dietitian to optimize your daily nutritional intake.


• Connect with the 347 members of the DiseaseMaps.org IgA nephropathy community to share experiences and coping strategies.


• Review clinical trial databases like ClinicalTrials.gov to see if you are a candidate for emerging research studies.

Medical disclaimer: This information is for educational purposes only and does not constitute medical advice; always consult your personal physician for diagnosis and treatment decisions specific to your health status.

References

• KDIGO Clinical Practice Guideline for the Management of Glomerular Diseases.


• National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) - IgA Nephropathy.


• NIH Genetic and Rare Diseases Information Center (GARD) - IgA Nephropathy.


• Orphanet: Portal for rare diseases and orphan drugs.